Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion

Çelik, Erkan; Doğan, Emine; Türkoğlu, Elif Betül; Çakır, Burçin; Alagöz, Gürsoy

doi:10.5935/0004-2749.20160004

Cited by 16 publications

(7 citation statements)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SRD is a common form of macular edema secondary to RVO. Celık and colleagues found that BRVO patients with SRD presented with worse VA and thicker central macular thickness compared with those with only cystoid macular edema [12]. Several studies from literature have shown significant improvement in RVO patients with SRD both functionally and morphologically.…”

Section: Discussionmentioning

confidence: 99%

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Chen

Yuan

Sun

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate choroid thickness and macular retinal metrics in treatment naïve retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter. Methods This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4-6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype. Results In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05). Conclusion Thicker choroid was a feature of naïve RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Chen

Yuan

Sun

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Серозная отслойка сетчатки с макулярным отеком в наружных слоях сетчатки -редко встречающаяся клиническая картина. Описанный симптомо-комплекс наблюдается также при окклюзиях вен сетчатки [43], но дифференциальная диагностика ретинальных окклюзий и осложнений антибиотикопрофилактики не представляет трудностей. В дифференциальной диагностике токсико-аллергической реакции на цефуроксим и синдрома Ирвина-Гасса, центральной серозной хориоретинопатии, макулопатии, ассоциированной с ямкой или диском зрительного нерва, и иных известных состояний с макулярным отеком и отслойкой пигментного и нейроэпителия может помочь ряд признаков.…”

Section: анафилаксияunclassified

Complications of intracameral cefuroxime in cataract surgery

Svetozarskiy

Андреев

2018

Vestn. oftal'mol.

View full text Add to dashboard Cite

Распространенность катаракты в России составляет около 3,5%, ежегодно проводится 470 000 операций по экстракции катаракты [1]. Одно из самых опасных осложнений факоэмульсификацииострый послеоперационный эндофтальмит, который развивается в 0,023-0,053% случаев и грозит потерей зрительных функций и глаза как органа [2, 3]. Его профилактика основана на реализации принципов асептики и антисептики и включает заблаговремен

show abstract

“…In addition, Demircan et al concluded that SRD height decrease is significantly greater in patients injected DEX than those injected ranibizumab. 26 , 36 , 37 However, few studies have focused on differences between the AIM and AVF responses of SRD height caused by RVO. We evaluated SRD changes in patients with RVO-ME to explore whether SRD could be a biomarker guiding a proper treatment.…”

Section: Discussionmentioning

confidence: 99%

Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies

Ding¹,

Hu²,

Yu³

et al. 2022

DDDT

View full text Add to dashboard Cite

Purpose This study aimed to assess the short-term changes of macular microstructures following anti-VEGF and anti-inflammatory therapies in patients with macular edema secondary to retinal vein occlusion (RVO-ME). Patients and Methods In this retrospective study, 70 eyes of 70 patients with RVO-ME were divided into the anti-VEGF (Group A, 35 eyes) and anti-inflammatory (Group B, 35 eyes) treatment groups. All patients underwent best-corrected visual acuity (BCVA) assessment, intraocular pressure (IOP) assessment, slit lamp, fundus fluorescein angiography (FA), scanning laser ophthalmoscopy (SLO), and spectral-domain optical coherence tomography (SD-OCT). Group A received intravitreal injection of 0.05 mL anti-VEGF antibodies (Lucentis ® or Aflibercept ® ) monthly for 3 consecutive months, while Group B received 0.7 mg dexamethasone (Ozurdex ® ) single intravitreal injection. BCVA and SD-OCT biomarkers were recorded at baseline and 3 months after the first injection. Changes of BCVA and SD-OCT biomarkers following these treatments were compared between the two groups. Results BCVA and SD-OCT biomarkers, except choroidal thickness, in both groups were significantly improved after treatment (all P < 0.01). At 3 months, the height of serous retinal detachment (SRD) was markedly lower ( P = 0.006), with significantly less hyperreflective dots (HRD, P = 0.037) in Group B compared with Group A. Other SD-OCT biomarkers and BCVA were not significantly different between the two groups (all P > 0.05). Conclusion Anti-VEGF and anti-inflammatory therapies are both effective in RVO-ME, with improvement in BCVA and SD-OCT biomarkers. Anti-inflammatory therapy may be more effective than anti-VEGF therapy in SRD and HRD resolution.

show abstract

Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion

Cited by 16 publications

References 23 publications

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Complications of intracameral cefuroxime in cataract surgery

Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies

Contact Info

Product

Resources

About